-
1دورية أكاديمية
المؤلفون: Minh H Dinh, Meegan R Anderson, Michael D McRaven, Gianguido C Cianci, Scott G McCoombe, Z L Kelley, Casey J Gioia, Angela J Fought, Alfred W Rademaker, Ronald S Veazey, Thomas J Hope
المصدر: PLoS Pathogens, Vol 11, Iss 3, p e1004729 (2015)
مصطلحات موضوعية: Immunologic diseases. Allergy, RC581-607, Biology (General), QH301-705.5
وصف الملف: electronic resource
-
2دورية أكاديمية
المؤلفون: Minh H Dinh, Taha Hirbod, Godfrey Kigozi, Eneniziaogochukwu A Okocha, Gianguido C Cianci, Xiangrong Kong, Jessica L Prodger, Kristina Broliden, Rupert Kaul, David Serwadda, Maria J Wawer, Ronald H Gray, Thomas J Hope
المصدر: PLoS ONE, Vol 7, Iss 7, p e41271 (2012)
وصف الملف: electronic resource
-
3
المؤلفون: Benoit You, Vasudha Sehgal, Balakrishna Hosmane, Xin Huang, Peter J. Ansell, Minh H. Dinh, Katherine Bell-McGuinn, Xizhi Luo, Gini F. Fleming, Michael Friedlander, Michael A. Bookman, Kathleen N. Moore, Karina D. Steffensen, Robert L. Coleman, Elizabeth M. Swisher
المصدر: Journal of Clinical Oncology. 41:107-116
مصطلحات موضوعية: Ovarian Neoplasms, Adenosine Diphosphate, Cancer Research, Paclitaxel, Oncology, Ribose, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Carboplatin
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee414e0d0c751db9a7fdfec855af7a92
https://doi.org/10.1200/jco.22.00430 -
4
المؤلفون: D. Ross Camidge, Martin Dunbar, Jyoti D. Patel, Jeffrey M. Clarke, Bruce A. Bach, Eddie Thara, Francisco Robert, Silpa Nuthalapati, Ebenezer A. Kio, Minh H. Dinh
المصدر: Lung Cancer. 161:180-188
مصطلحات موضوعية: Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Veliparib, medicine.medical_treatment, chemistry.chemical_compound, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Lung cancer, Platinum, Chemotherapy, business.industry, Combination chemotherapy, medicine.disease, Carboplatin, Nivolumab, Pemetrexed, Tolerability, chemistry, Benzimidazoles, business, medicine.drug
-
5
المؤلفون: Aikou Okamoto, Ana Oaknin, Elizabeth M. Swisher, Shibani Nicum, Mika Mizuno, Robert L. Coleman, Karina Dahl Steffensen, Sudipta Bhattacharya, Gini F. Fleming, Paul DiSilvestro, Mark A. Morgan, Charles A. Leath, Peter Ansell, Christine K. Ratajczak, Andrea R. Hagemann, Carol Aghajanian, Kathleen N. Moore, Michael Friedlander, Joo-Hyun Nam, Danielle Sullivan, Noa Ben-Baruch, Katherine M. Bell-McGuinn, Minh H. Dinh, Bruce A. Bach, Michael A. Bookman, Theresa L. Werner, Mark F. Brady, Jesús García-Donas, N.G. Cloven, Sally Baron-Hay, Ramey D. Littell, David Cella
المصدر: Coleman, R L, Fleming, G F, Brady, M F, Swisher, E M, Steffensen, K D, Friedlander, M, Okamoto, A, Moore, K N, Efrat Ben-Baruch, N, Werner, T L, Cloven, N G, Oaknin, A, DiSilvestro, P A, Morgan, M A, Nam, J-H, Leath, C A, Nicum, S, Hagemann, A R, Littell, R D, Cella, D, Baron-Hay, S, Garcia-Donas, J, Mizuno, M, Bell-McGuinn, K, Sullivan, D M, Bach, B A, Bhattacharya, S, Ratajczak, C K, Ansell, P J, Dinh, M H, Aghajanian, C & Bookman, M A 2019, ' Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer ', The New England Journal of Medicine, vol. 381, no. 25, pp. 2403-2415 . https://doi.org/10.1056/NEJMoa1909707
مصطلحات موضوعية: Oncology, Benzimidazoles/adverse effects, medicine.medical_treatment, Genes, BRCA2, Genes, BRCA1, Administration, Oral, 030204 cardiovascular system & hematology, Carboplatin, chemistry.chemical_compound, 0302 clinical medicine, Maintenance therapy, Antineoplastic Combined Chemotherapy Protocols, 030212 general & internal medicine, Ovarian Neoplasms, Aged, 80 and over, Cystadenocarcinoma, Serous/drug therapy, Ovarian Neoplasms/drug therapy, General Medicine, Middle Aged, Combined Modality Therapy, Progression-Free Survival, Intention to Treat Analysis, Female, Adult, medicine.medical_specialty, Paclitaxel, Veliparib, Poly(ADP-ribose) Polymerase Inhibitors, Article, Maintenance Chemotherapy, 03 medical and health sciences, Double-Blind Method, Paclitaxel/administration & dosage, Internal medicine, medicine, Humans, Progression-free survival, Aged, Chemotherapy, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Carboplatin/administration & dosage, medicine.disease, Cystadenocarcinoma, Serous, Clinical trial, Adenosine diphosphate, chemistry, Mutation, Quality of Life, Benzimidazoles, Ovarian cancer, business, Poly(ADP-ribose) Polymerase Inhibitors/adverse effects
وصف الملف: application/pdf
-
6
المؤلفون: Elizabeth M. Swisher, Carol Aghajanian, David M. O'Malley, Gini F. Fleming, Scott H. Kaufmann, Douglas A. Levine, Michael J. Birrer, Kathleen N. Moore, Nick M. Spirtos, Mark S. Shahin, Thomas J. Reid, Michael Friedlander, Karina Dahl Steffensen, Aikou Okamoto, Vasudha Sehgal, Peter J. Ansell, Minh H. Dinh, Michael A. Bookman, Robert L. Coleman
المصدر: Swisher, E M, Aghajanian, C, O'Malley, D M, Fleming, G F, Kaufmann, S H, Levine, D A, Birrer, M J, Moore, K N, Spirtos, N M, Shahin, M S, Reid, T J, Friedlander, M, Steffensen, K D, Okamoto, A, Sehgal, V, Ansell, P J, Dinh, M H, Bookman, M A & Coleman, R L 2022, ' Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study ', Gynecologic Oncology, vol. 164, no. 2, pp. 245-253 . https://doi.org/10.1016/j.ygyno.2021.12.003
مصطلحات موضوعية: Adult, Paclitaxel, Genes, BRCA2, Genes, BRCA1, Loss of Heterozygosity, Allelic Imbalance, Carcinoma, Ovarian Epithelial, Poly(ADP-ribose) Polymerase Inhibitors, Genomic Instability, Carboplatin, Maintenance Chemotherapy, Young Adult, BRCA1/2, Antineoplastic Combined Chemotherapy Protocols, Humans, Aged, Neoplasm Staging, Proportional Hazards Models, Aged, 80 and over, Ovarian Neoplasms, Veliparib, Recombinational DNA Repair, Obstetrics and Gynecology, Cytoreduction Surgical Procedures, Induction Chemotherapy, General Medicine, Middle Aged, Progression-Free Survival, Oncology, CA-125 Antigen, Hereditary Breast and Ovarian Cancer Syndrome, Benzimidazoles, Female, Homologous recombination deficiency
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4581455fdf487d12d2578e534388cdd5
https://doi.org/10.1097/01.ogx.0000827620.82650.68 -
7
المؤلفون: Peter Ansell, Karina Dahl Steffensen, Kathleen N. Moore, Aikou Okamoto, Christine K. Ratajczak, Danielle Sullivan, Robert L. Coleman, Minh H. Dinh, Brenden Chen, Scott H. Kaufmann, Bruce A. Bach, Elizabeth M. Swisher, Michael A. Bookman
المصدر: Swisher, E, Kaufmann, S, Okamoto, A, Steffensen, K, Bookman, M, Moore, K, Sullivan, D, Bach, B, Ratajczak, C, Chen, B, Dinh, M, Ansell, P & Coleman, R 2021, ' Characterization of patients with BRCA mutated ovarian cancer who are eligible versus not eligible for PARP inhibitor maintenance therapy: exploratory analysis of the VELIA study ', Gynecologic Oncology, vol. 162, no. Suppl. 1, pp. S106-S107 . https://doi.org/10.1016/S0090-8258(21)00846-5
مصطلحات موضوعية: Oncology, medicine.medical_specialty, Chemotherapy, Performance status, Veliparib, business.industry, medicine.medical_treatment, Obstetrics and Gynecology, medicine.disease, Placebo, Carboplatin, Olaparib, chemistry.chemical_compound, chemistry, Maintenance therapy, Internal medicine, otorhinolaryngologic diseases, Medicine, business, Progressive disease
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88d5f71e65265838f2a5eddbbaef9d45
https://portal.findresearcher.sdu.dk/da/publications/05d497fe-54cd-4876-920b-a4892131e8dd -
8
المؤلفون: David Cella, N. Khandelwal, K. Benjamin, Danielle Sullivan, Robert L. Coleman, M. A. Bookman, Minh H. Dinh, Rajesh Kamalakar, Angeles Alvarez Secord
المصدر: Oral Plenary.
مصطلحات موضوعية: Oncology, medicine.medical_specialty, Veliparib, business.industry, Nausea, Placebo, medicine.disease, chemistry.chemical_compound, chemistry, Internal medicine, Toxicity, medicine, Vomiting, Progression-free survival, medicine.symptom, Adverse effect, business, Ovarian cancer
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::7dafafb2d2ffbaf512039accdfd69052
https://doi.org/10.1136/ijgc-2020-igcs.16 -
9
المؤلفون: Minh H. Dinh, Theresa L. Werner, Danielle Sullivan, Robert L. Coleman, Michael Friedlander, Peter Ansell, Aikou Okamoto, David Cella, Shibani Nicum, Gini F. Fleming, Michael A. Bookman, Joo-Hyun Nam, Carol Aghajanian, Karina Dahl Steffensen, Charles A. Leath, Ana Oaknin, Kathleen N. Moore, Noa Ben-Baruch, Elizabeth M. Swisher, Mark F. Brady
المصدر: Coleman, R L, Fleming, G F, Brady, M F, Swisher, E, Steffensen, K D, Friedlander, M, Okamoto, A, Moore, K, Ben-Baruch, N, Werner, T L, Oaknin, A, Nam, J-H, Leath III, C A, Nicum, S, Cella, D, Sullivan, D M, Ansell, P J, Dinh, M, Aghajanian, C & Bookman, M A 2019, ' VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC) ', Annals of Oncology, vol. 30, no. Suppl. 5, LBA3, pp. 895-896 . https://doi.org/10.1093/annonc/mdz394.054
مصطلحات موضوعية: Oncology, medicine.medical_specialty, Veliparib, business.industry, Serous cystadenocarcinoma, Hematology, Debulking, medicine.disease, Chemotherapy regimen, Carboplatin, chemistry.chemical_compound, medicine.anatomical_structure, chemistry, Peritoneum, Internal medicine, medicine, Progression-free survival, business, Fallopian tube
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4ba78554549a175a0c325f3783e0c9a
https://portal.findresearcher.sdu.dk/da/publications/ac0d1969-1c86-4c6d-944a-80a0f8a178b0 -
10
المؤلفون: Kirsten Timms, Gini F. Fleming, Robert L. Coleman, Michael A. Bookman, Danielle Sullivan, Scott H. Kaufmann, Michael J. Birrer, Bruce A. Bach, Douglas A. Levine, Minh H. Dinh, Vasudha Sehgal, Kathleen N. Moore, Peter Ansell, Carol Aghajanian, Elizabeth M. Swisher, Brenden Chen
المصدر: Gynecologic Oncology. 159:51
مصطلحات موضوعية: Veliparib, business.industry, Wild type, Obstetrics and Gynecology, Carboplatin/paclitaxel, chemistry.chemical_compound, Oncology, chemistry, Ovarian carcinoma, Cancer research, Medicine, Progression-free survival, Homologous recombination, business